Home › Plaveiselcelcarcinoom van hoofd en hals › Georgia › Atlanta
Plaveiselcelcarcinoom van hoofd en hals klinische studies in Atlanta, GA
24 studies voor Plaveiselcelcarcinoom van hoofd en hals zoeken deelnemers op locaties in en rond Atlanta (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruterenFase 1
- Emory University, Atlanta
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
RekruterenFase 3
- Emory University, Atlanta
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RekruterenFase 2
- Emory University Hospital Midtown, Atlanta
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
RekruterenFase 3
- Emory University Hospital Midtown, Atlanta
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
RekruterenFase 1
- Emory University, Atlanta
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
RekruterenFase 2
- Emory Proton Therapy Center, Atlanta
- Emory University Hospital Midtown, Atlanta
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RekruterenFase 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
RekruterenObservatieonderzoek
- Morehouse, Atlanta
- Piedmont Healthcare, Atlanta
- Winship Cancer Institute, Emory University, Atlanta
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RekruterenFase 2
- Emory University School of Medicine, Atlanta
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
RekruterenFase 2/3
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RekruterenFase 1/2
- Winship Cancer Institute - Emory University, Atlanta
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
RekruterenFase 1/2
- Emory University, Atlanta
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Rekruteren
- Emory Midtown University Hospital/Winship Cancer Institute, Atlanta
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RekruterenFase 1/2
- Winship Cancer Institute, Emory University, Atlanta
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
RekruterenFase 3
- GSK Investigational Site, Atlanta
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
RekruterenFase 2
- USA10-0, Atlanta
Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial
Rekruteren
- Emory University Hospital, Atlanta
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
RekruterenFase 3
- Emory University, Atlanta
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
RekruterenFase 1/2
- Research Site 111, Atlanta
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
RekruterenFase 1
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
RekruterenFase 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RekruterenFase 1/2
- Research Site 114, Atlanta
- Research Site 139, Atlanta
Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
RekruterenVroege fase 1
- Emory University Hospital Midtown, Atlanta
A Beta-only IL-2 ImmunoTherapY Study
RekruterenFase 1/2
- Emory - Winship Cancer Institute, Atlanta
Plaveiselcelcarcinoom van hoofd en hals studies in andere steden
- Houston, TX47 studies
- Los Angeles, CA42 studies
- Boston, MA40 studies
- New York City, NY39 studies
- Nashville, TN39 studies
- St. Louis, MO28 studies
- Arlington, VA26 studies
- Philadelphia, PA26 studies
- Chicago, IL26 studies
- San Antonio, TX22 studies
- New Haven, CT22 studies
- Pittsburgh, PA22 studies
Andere studies in Atlanta
- Kanker (alle vormen)49 studies
- Niet-kleincellige longkanker47 studies
- Multipel myeloom42 studies
- Borstkanker41 studies
- Prostaatkanker33 studies
- Acute myeloïde leukemie31 studies
- Eierstokkanker29 studies
- Colorectale kanker29 studies
- Longkanker29 studies
- Metastatische kanker28 studies
- Ernstige depressieve stoornis25 studies
- Hartfalen25 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.